Key result
Amiodarone exposure for 2 years in a pediatric patient with hypertrophic cardiomyopathy resulted in severe pulmonary toxicity, resolving after drug cessation and corticosteroid therapy.
Why the study?
The study was conducted to draw attention to pulmonary toxicity due to amiodarone administration.
Case Report (n=1)
Amiodarone can cause severe pulmonary toxicity in pediatric patients, requiring prompt drug discontinuation and potentially corticosteroid therapy and mechanical ventilation.
Amiodarone pulmonary toxicity warrants monitoring in pediatric patients; this case leaves open the need for prospective safety studies in hypertrophic cardiomyopathy.
Amiodarone is an antiarrhythmic medication used for the treatment of ventricular tachycardia. In addition to unwanted effects in many tissues, one of the most important side effects of the drug is pulmonary toxicity. Toxicity may develop at any time after administration to the drug, and the risk increases depending on the dose and duration of the treatment. Clinical and laboratory findings are non-specific. In treatment, amiodarone is discontinued. In severe cases, corticosteroid therapy can be started. Here, we present the case of a patient who was followed up for two years for hypertrophic cardiomyopathy and presented to the pediatric emergency department with hemoptysis, dizziness clouding of consciousness and numb tongue. Amiodarone was used for two years to treat ventricular arrhythmia. The findings of the patient at presentation were thought to be due to amiodarone pulmonary toxicity. Amiodarone was stopped and corticosteroid therapy was initiated. Non-invasive mechanical ventilation was applied for 3 days. On the 8 th day of hospitalization, the patient was transferred to the ward. The aim of this case report was to draw attention to pulmonary toxicity due to amiodarone administration.
No takes yet. Share an insight, caveat, or question.
Arslan et al. (2019) conducted a case report in Amiodarone pulmonary toxicity (n=1). Amiodarone was evaluated. Amiodarone exposure for 2 years in a pediatric patient with hypertrophic cardiomyopathy resulted in severe pulmonary toxicity, resolving after drug cessation and corticosteroid therapy.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: